Search research articles
Contact Us
Filters
Showing results (111-120 of 174) with videos related to
Page
of 18
Sort By:
British Journal of Cancer
|
May 24, 2023
Six-year experience of Australia's first dedicated cancer of unknown primary clinic
Arielle van Mourik, Gina Tonkin-Hill, John O'Farrell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Osnat Elyashiv, Jonathan Ledermann, Gita Parmar, et al.
Australian Health Review : a Publication of the Australian Hospital Association
|
December 1, 2011
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment
Senthil Lingaratnam, Leon J Worth, Monica A Slavin, et al.
Nature Communications
|
November 14, 2024
Unravelling mutational signatures with plasma circulating tumour DNA
Sebastian Hollizeck, Ning Wang, Stephen Q Wong, et al.
The Oncologist
|
March 9, 2021
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
Chantal Pauli, Tilmann Bochtler, Linda Mileshkin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 16, 2008
In vivo tracking of dendritic cells in patients with multiple myeloma
H Miles Prince, Dominic M Wall, David Ritchie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2018
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Sarah P Blagden, Anne L Hamilton, Linda Mileshkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M O'Malley, Giovanni Mendonca Bariani, Philippe A Cassier, et al.
Gynecologic Oncology
|
January 23, 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
David M O'Malley, Giovani M Bariani, Philippe A Cassier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2005
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
H Miles Prince, Linda Mileshkin, Andrew Roberts, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 174) with videos related to
Sort By:
Page
of 18
British Journal of Cancer
|
May 24, 2023
Six-year experience of Australia's first dedicated cancer of unknown primary clinic
Arielle van Mourik, Gina Tonkin-Hill, John O'Farrell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Osnat Elyashiv, Jonathan Ledermann, Gita Parmar, et al.
Australian Health Review : a Publication of the Australian Hospital Association
|
December 1, 2011
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment
Senthil Lingaratnam, Leon J Worth, Monica A Slavin, et al.
Nature Communications
|
November 14, 2024
Unravelling mutational signatures with plasma circulating tumour DNA
Sebastian Hollizeck, Ning Wang, Stephen Q Wong, et al.
The Oncologist
|
March 9, 2021
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience
Chantal Pauli, Tilmann Bochtler, Linda Mileshkin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
May 16, 2008
In vivo tracking of dendritic cells in patients with multiple myeloma
H Miles Prince, Dominic M Wall, David Ritchie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 20, 2018
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Sarah P Blagden, Anne L Hamilton, Linda Mileshkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2022
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
David M O'Malley, Giovanni Mendonca Bariani, Philippe A Cassier, et al.
Gynecologic Oncology
|
January 23, 2025
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
David M O'Malley, Giovani M Bariani, Philippe A Cassier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2005
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
H Miles Prince, Linda Mileshkin, Andrew Roberts, et al.
Page
of 18